Cargando…
MicroRNA-20a-5p Downregulation by Atorvastatin: A Potential Mechanism Involved in Lipid-Lowering Therapy
The treatment of hypercholesterolemia is mainly based on statins. However, the response to pharmacological therapy shows high inter-individual variability, resulting in variable effects in both lipid lowering and risk reduction. Thus, a better understanding of the lipid-lowering mechanisms and respo...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9104095/ https://www.ncbi.nlm.nih.gov/pubmed/35563413 http://dx.doi.org/10.3390/ijms23095022 |
_version_ | 1784707710970757120 |
---|---|
author | Saavedra, Kathleen Leal, Karla Saavedra, Nicolás Prado, Yalena Paez, Isis Ubilla, Carmen G. Rojas, Gabriel Salazar, Luis A. |
author_facet | Saavedra, Kathleen Leal, Karla Saavedra, Nicolás Prado, Yalena Paez, Isis Ubilla, Carmen G. Rojas, Gabriel Salazar, Luis A. |
author_sort | Saavedra, Kathleen |
collection | PubMed |
description | The treatment of hypercholesterolemia is mainly based on statins. However, the response to pharmacological therapy shows high inter-individual variability, resulting in variable effects in both lipid lowering and risk reduction. Thus, a better understanding of the lipid-lowering mechanisms and response variability at the molecular level is required. Previously, we demonstrated a deregulation of the microRNA expression profile in HepG2 cells treated for 24 h with atorvastatin, using a microarray platform. In the present study, we evaluated the expression of hsa-miR-17-5p, hsa-miR-20a-5p and hsa-miR-106a-5p in hypercholesterolemic patients before and after atorvastatin treatment and in HepG2 cells treated for 24 h with atorvastatin The miRNA hsa-mir-20a-5p was repressed after atorvastatin treatment in hypercholesteremic subjects and in HepG2 cells in culture. Repression of hsa-mir-20a-5p increased LDLR gene and protein expression in HepG2 cells, while hsa-mir-20a-5p overexpression reduced LDLR gene and protein expression. |
format | Online Article Text |
id | pubmed-9104095 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91040952022-05-14 MicroRNA-20a-5p Downregulation by Atorvastatin: A Potential Mechanism Involved in Lipid-Lowering Therapy Saavedra, Kathleen Leal, Karla Saavedra, Nicolás Prado, Yalena Paez, Isis Ubilla, Carmen G. Rojas, Gabriel Salazar, Luis A. Int J Mol Sci Article The treatment of hypercholesterolemia is mainly based on statins. However, the response to pharmacological therapy shows high inter-individual variability, resulting in variable effects in both lipid lowering and risk reduction. Thus, a better understanding of the lipid-lowering mechanisms and response variability at the molecular level is required. Previously, we demonstrated a deregulation of the microRNA expression profile in HepG2 cells treated for 24 h with atorvastatin, using a microarray platform. In the present study, we evaluated the expression of hsa-miR-17-5p, hsa-miR-20a-5p and hsa-miR-106a-5p in hypercholesterolemic patients before and after atorvastatin treatment and in HepG2 cells treated for 24 h with atorvastatin The miRNA hsa-mir-20a-5p was repressed after atorvastatin treatment in hypercholesteremic subjects and in HepG2 cells in culture. Repression of hsa-mir-20a-5p increased LDLR gene and protein expression in HepG2 cells, while hsa-mir-20a-5p overexpression reduced LDLR gene and protein expression. MDPI 2022-04-30 /pmc/articles/PMC9104095/ /pubmed/35563413 http://dx.doi.org/10.3390/ijms23095022 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Saavedra, Kathleen Leal, Karla Saavedra, Nicolás Prado, Yalena Paez, Isis Ubilla, Carmen G. Rojas, Gabriel Salazar, Luis A. MicroRNA-20a-5p Downregulation by Atorvastatin: A Potential Mechanism Involved in Lipid-Lowering Therapy |
title | MicroRNA-20a-5p Downregulation by Atorvastatin: A Potential Mechanism Involved in Lipid-Lowering Therapy |
title_full | MicroRNA-20a-5p Downregulation by Atorvastatin: A Potential Mechanism Involved in Lipid-Lowering Therapy |
title_fullStr | MicroRNA-20a-5p Downregulation by Atorvastatin: A Potential Mechanism Involved in Lipid-Lowering Therapy |
title_full_unstemmed | MicroRNA-20a-5p Downregulation by Atorvastatin: A Potential Mechanism Involved in Lipid-Lowering Therapy |
title_short | MicroRNA-20a-5p Downregulation by Atorvastatin: A Potential Mechanism Involved in Lipid-Lowering Therapy |
title_sort | microrna-20a-5p downregulation by atorvastatin: a potential mechanism involved in lipid-lowering therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9104095/ https://www.ncbi.nlm.nih.gov/pubmed/35563413 http://dx.doi.org/10.3390/ijms23095022 |
work_keys_str_mv | AT saavedrakathleen microrna20a5pdownregulationbyatorvastatinapotentialmechanisminvolvedinlipidloweringtherapy AT lealkarla microrna20a5pdownregulationbyatorvastatinapotentialmechanisminvolvedinlipidloweringtherapy AT saavedranicolas microrna20a5pdownregulationbyatorvastatinapotentialmechanisminvolvedinlipidloweringtherapy AT pradoyalena microrna20a5pdownregulationbyatorvastatinapotentialmechanisminvolvedinlipidloweringtherapy AT paezisis microrna20a5pdownregulationbyatorvastatinapotentialmechanisminvolvedinlipidloweringtherapy AT ubillacarmeng microrna20a5pdownregulationbyatorvastatinapotentialmechanisminvolvedinlipidloweringtherapy AT rojasgabriel microrna20a5pdownregulationbyatorvastatinapotentialmechanisminvolvedinlipidloweringtherapy AT salazarluisa microrna20a5pdownregulationbyatorvastatinapotentialmechanisminvolvedinlipidloweringtherapy |